Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The World Health Organization (WHO) has released its 2025 Global Antimicrobial Resistance and Use Surveillance (GLASS) Report, offering the most comprehensive global data on antimicrobial resistance (AMR) to date. Among the contributors were OUCRU Indonesia’s Professor Raph Hamers and Dr Gilbert Lazarus, whose systematic reviews provided critical insights into resistance trends. Their findings highlight rising resistance, especially in low-resource settings, and underscore the need for stronger surveillance and evidence-informed policy to address this growing health threat.

Researcher holding a test tube

The World Health Organization (WHO) has published its latest Global Antimicrobial Resistance and Use Surveillance (GLASS) Report, drawing on data from 104 countries. The 2025 edition reveals increasing resistance among common pathogens, especially in regions with limited diagnostic capacity, and highlights the need for safer antibiotic use and improved global surveillance.

A major contribution to the report came from OUCRU Indonesia. Professor Raph Hamers and Dr Gilbert Lazarus led systematic reviews comparing global antibiotic resistance data reported in peer-reviewed literature (2018–2023) with WHO’s GLASS surveillance findings. Their work, featured in Chapter 4, found that resistance levels in published studies—often from large hospitals—were sometimes higher than those captured in national surveillance systems. Nevertheless, both sources confirmed widespread and rising resistance in key bacteria like Acinetobacter spp., Staphylococcus aureus, and Salmonella spp.

“Contributing to this important WHO report is part of OUCRU’s commitment to advancing evidence-based research on antimicrobial resistance,” said Raph, Head of the Clinical Infectious Diseases Research Programme at OUCRU Indonesia. “We are proud to work alongside WHO and partners to help strengthen the global evidence base needed for better policy and action.” 

OUCRU’s contributions reflect its strong commitment to evidence-based research on AMR. Ongoing projects such as ACORN, NASPA, and the PRYSMA trial continue to support regional and global action to combat AMR.

Visit the Global antibiotic resistance surveillance report 2025 on the WHO website

The full story is available on the OUCRU website